

## HitGen partners with Howard Hughes Medical Institute and Duke University

18 March 2022 | News

### HitGen announces research collaboration focused on DNA-Encoded library based drug discovery



HitGen has entered into a research collaboration agreement with Howard Hughes Medical Institute ("HHMI") and Duke University. The Principal Investigators for HHMI and Duke University who will oversee the collaboration will be Dr. Robert J. Lefkowitz, a James B. Duke Professor of Medicine and Professor of Biochemistry and Chemistry at the Duke University Medical Center, Investigator of the Howard Hughes Medical Institute as well as the recipient of the 2012 Nobel Prize in Chemistry, and Dr. Howard A. Rockman, an Edward S. Orgain Distinguished Professor of Cardiology and Professor of Medicine and Cell Biology at the Duke University Medical Center. HHMI and Duke University will use HitGen's OpenDEL<sup>®</sup> to perform selections against GPCR targets. OpenDEL<sup>®</sup> is an affordable self-service drug discovery DEL platform for start-ups, biotechs, and academic researchers.

"We look forward to working with the Lefkowitz-Rockman team at HHMI and Duke University and believe that the collaboration reinforces the role of HitGen's platform as a leader in the rapidly developing field of DNA-encoded chemistry," said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen Inc.

HitGen is a world leader in the development of the DEL technology and applications to early-stage small molecule drug discovery. HitGen's full range of DEL products and the efficiency of the screening process have made it possible for HitGen to enable drug discovery projects for many organizations around the world.